MIMETAS Expands Adult Stem Cell Organoid License to All Organs

May 03, 2022

MIMETAS Expands Adult Stem Cell Organoid License to All Organs

Leiden, The Netherlands, May 3, 2022 – MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today that it has expanded its license to the HUB Organoid Technology to include all organs. The license covers organoid technology developed by Professor Hans Clevers, a pioneer in adult stem cells.

“This is a crucial addition to our Organ-on-a-Chip disease models,” says Jos Joore, co-CEO of MIMETAS. “We typically combine HUB Organoids® with MIMETAS’ OrganoPlate® technology, adding connective tissues, vasculature, and immune cells. Thus, we create the most advanced organ mimics currently available. These miniature organs are used to develop therapies against incurable diseases, such as inflammatory bowel disease and liver fibrosis. With this expanded license, we will be able to broaden our use of adult stem cell-derived organoids to even more indications.”

HUB manages a world-leading patent portfolio for adult stem cell-derived organoid technology, originally developed in the lab of Professor Hans Clevers. Chief Business Officer of HUB Bahar Ramezanpour confirms, “We are delighted to expand our excellent collaboration with Mimetas. This ensures maximum utilization of two great technologies for the benefit of patients. In addition, Mimetas will now be able to expand its offering to other organs such as lung, kidney, and pancreas.”

Since its foundation in 2013, MIMETAS has collaborated extensively with the group of Professor Hans Clevers. This collaboration has resulted in a range of publications, including on the integration of kidney organoids1, 2 in the MIMETAS OrganoPlate and vascularization of liver organoids3. Clevers’ technology utilizes the regenerative capacity of patient-derived adult stem cells to reproduce organ functionality in the laboratory. A key difference between Clevers’ technology and embryonic and induced pluripotent stem cells is that the properties of the donor, including specific disease aspects, are maintained when cultured outside of the human body.


References
1Schutgens et al., 2019 Nature Biotechnology
2Gijssen et al., 2021 Nature Protocols
3Bonanini et al., 2022 in press

Home > News > MIMETAS Expands Adult Stem Cell Organoid Licens...

© 2022 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds